Gesa Schalk

Bonn, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Development of an Exergaming-Intervention for Children and Adolescents During Hemodialysis: A Pilot Study.

Development of an Exergaming-Intervention for Children and Adolescents During Hemodialysis: A Pilot Study.

Journal: Studies in health technology and informatics

Published: May 12, 2026

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.

Journal: Kidney international reports

Published: December 20, 2024

Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3.

Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3.

Journal: Kidney international reports

Published: September 05, 2023

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).

Journal: Urolithiasis

Published: June 05, 2023

Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).

Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).

Journal: Urolithiasis

Published: February 17, 2023

ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.

ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.

Journal: Pediatric nephrology (Berlin, Germany)

Published: December 14, 2021

Early clinical course of biopsy-proven IgA vasculitis nephritis.

Early clinical course of biopsy-proven IgA vasculitis nephritis.

Journal: BMC pediatrics

Published: November 08, 2021

Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.

Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.

Journal: Kidney international

Published: May 13, 2021

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

Journal: The New England journal of medicine

Published: March 31, 2021

Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD).

Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD).

Journal: Scientific reports

Published: April 11, 2020

C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.

C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.

Journal: Frontiers in immunology

Published: December 09, 2018

Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity.

Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity.

Journal: Immunity & ageing : I & A

Published: November 18, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026